-

Kathy Spencer-Pike Joins NorthStar Medical Radioisotopes, LLC as Chief Commercial Officer

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer, effective December 1st 2025.

In this role, Spencer-Pike will lead the company’s commercial strategy; overseeing sales, marketing, business development, customer engagement and market expansion initiatives to drive growth and strengthen the company’s competitive position. She will work closely with cross-functional teams to align commercial initiatives with corporate objectives focused on ensuring sustainable growth and achieving market leadership.

“Kathy brings a wealth of experience in scaling commercial organizations and driving revenue growth,” said Frank Scholz, President and CEO of NorthStar Medical Radioisotopes. “Her strategic vision, sector experience and deep understanding of market dynamics will be key as we continue to strengthen our position and deliver value to our customers.”

Spencer-Pike brings more than 25 years of expertise in scaling commercial teams and driving sales effectiveness, creating and executing successful product launch cycles, and accelerating revenue generation in complex healthcare and life sciences environments. As an accomplished executive with a proven track record for pioneering innovative strategies that differentiate companies, expand markets and deliver lasting value, Spencer-Pike is expert at driving performance in Fortune 50 companies and high growth startups alike.

“I’m excited to join NorthStar as CCO at a time when demand for reliable isotope supply and end-to-end radiopharma solutions has never been greater. NorthStar is uniquely positioned to maximize opportunities presented by this momentum, scale rapidly, and become a catalyst for industry-wide progress. I look forward to building strong customer partnerships and driving commercial growth that advances business for NorthStar and our customers and enhances patient impact,” said Spencer-Pike.

Most recently, Spencer-Pike served as Chief Commercial Officer at Nucleus RadioPharma, where she led the development of commercial strategy, scaled marketing and business development capabilities, aligned cross-functional infrastructure, and supported readiness for clinical and commercial manufacturing. Previously, she held senior leadership roles at McKesson / CoverMyMeds, where she led a large commercial organization across three integrated businesses, driving double-digit growth and industry-leading client retention. Prior to that, Spencer-Pike held commercial leadership roles at Novo Nordisk, Sanofi and Pfizer.

Spencer-Pike holds a B.S. from Eastern Kentucky University, Richmond, Kentucky and a M.A. in Mental Health Counseling from Webster University, Orlando, Florida.

About NorthStar Medical Radioisotopes, LLC (NorthStar)

NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar’s expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar produces copper-67 (Cu-67) and is poised to be one of the first commercial-scale producers of non-carrier added actinium-225 (n.c.a. Ac-225). The Company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar’s comprehensive portfolio and patient-focused services. Visit: www.northstarnm.com.

Contacts

For NorthStar Medical Radioisotopes, LLC
Corporate:
Gauri Gupta
Vice President, Chief of Staff
312-288-5431
ggupta@northstarnm.com

NorthStar Medical Radioisotopes, LLC


Release Versions

Contacts

For NorthStar Medical Radioisotopes, LLC
Corporate:
Gauri Gupta
Vice President, Chief of Staff
312-288-5431
ggupta@northstarnm.com

More News From NorthStar Medical Radioisotopes, LLC

NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline

BASEL, Switzerland & MUNICH & BELOIT, Wis.--(BUSINESS WIRE)--NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, LLC (NorthStar), a global radiopharmaceutical supply-chain partner, today announced a long-term strategic partnership through which NorthStar will produce Copper-67 (Cu-67) and provide comprehensive radiopharmaceutical manufacturing services to support NUCLIDIUM's therapeutic programs from clinical development through commercialization. Cop...

NorthStar Expands Access to Commercial-Scale No-Carrier-Added Actinium-225 in China Through Quarkmed Partnership

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a strategic partnership with Quarkmed, a Beijing-based contract research organization (CRO) specializing in nuclear medicine and radiopharmaceutical clinical development, with expertise spanning pharmaceutical regulatory affairs, clinical development, and clinical trial operatio...

NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a multi-year growth capital facility of up to $185 million with Hercules Capital, Inc. (NYSE: HTGC) to support NorthStar’s continued growth and expansion. The financing, including $100 million upfront, will accelerate investment in isotope production and in clinical and commerci...
Back to Newsroom